The company received a notice of allowance from the U.S. Patent and Trademark Office for Exparel’s chemical composition, according to a news release. Pacira plans to submit the patent for listing in the FDA Approved Drug Products with Therapeutic Equivalence Evaluations.
Pacira also received a notice of allowance from the USPTO for a patent relating to a novel manufacturing process for Exparel.
Both patents will have an expiration date of Jan. 22, 2041.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
